Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 42

Results For "Scientific"

944 News Found

Novartis to acquire Mariana Oncology for upfront US$ 1 billion
News | May 03, 2024

Novartis to acquire Mariana Oncology for upfront US$ 1 billion

Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications


Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine
Clinical Trials | May 02, 2024

Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine

Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases


Novartis and Medicines for Malaria Venture announce positive efficacy and safety data
Clinical Trials | May 01, 2024

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data

The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg


PharmaLytica 2024 to draw 200+ exhibitors
News | April 19, 2024

PharmaLytica 2024 to draw 200+ exhibitors

10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad


Positive data for Roche multiple sclerosis injection
Drug Approval | April 17, 2024

Positive data for Roche multiple sclerosis injection

US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024


Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024
Clinical Trials | April 16, 2024

Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024

Global Phase-3 study initiation expected in the second half of 2024


Pfizer announces positive results from Phase 3 Study of Abrysvo
Clinical Trials | April 12, 2024

Pfizer announces positive results from Phase 3 Study of Abrysvo

ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.


Evonik launches Botanicals & Natural Actives business segment
News | April 11, 2024

Evonik launches Botanicals & Natural Actives business segment

Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market